MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Public ClinicalTrials.gov record NCT00072930. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Randomized, Open-Label, Two-Arm, Multicenter Study of MEDI-522, a HuMA Directed Against the Human Alpha V Beta 3 Integrin, in Combination With Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC); and 2. To summarize the safety of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in this patient population.
Study identification
- NCT ID
- NCT00072930
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2003 (Type not available)
- Primary completion
- Apr 2007 (Estimated)
- Completion
- Jun 2007 (Actual)
- Last update posted
- Jan 15, 2008
2003 – 2007
United States locations
- U.S. sites
- 36
- U.S. states
- 21
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Consultants, Inc. | Hoover | Alabama | 35216 | — |
| Highlands Oncology Group, P.A. | Springdale | Arizona | 72764 | — |
| Arizona Hematology-Oncology, P.C. | Tucson | Arizona | 85704 | — |
| South Valley Medical Plaza | Gilroy | California | 95020-3535 | — |
| San Bernardino Urological Associates | San Bernardino | California | 92404 | — |
| Saint Francis Memorial Hospital | San Francisco | California | 94109 | — |
| Stanford Advanced Medical Center | Stanford | California | 94305-5826 | — |
| Florida Cancer Specialist | Fort Myers | Florida | 33901 | — |
| The Florida Wellcare Alliance, L.C. | Inverness | Florida | 34452 | — |
| Hemotology/Oncology Associates | Lake Worth | Florida | — | — |
| Hawaii Medical Consultants | Honolulu | Hawaii | 96817 | — |
| University of Chicago | Chicago | Illinois | 60637-1470 | — |
| Ingalls Hospital | Harvey | Illinois | 60426 | — |
| The Community Hospital | Munster | Indiana | 46321 | — |
| Hematology Oncology Services, LLC | New Orleans | Louisiana | 70115 | — |
| Hubert H. Humphrey Cancer Center | Robbinsdale | Minnesota | 55422 | — |
| North Mississippi Hematology & Oncology Associates, Ltd. | Tupelo | Mississippi | 38801 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110-1010 | — |
| Comprehensive Cancer Center of Nevada | Las Vegas | Nevada | 89109 | — |
| VA Sierra Nevada Health Care System | Reno | Nevada | 89502 | — |
| New Mexico Oncology Hematology, Consultants Ltd. | Albuquerque | New Mexico | 87109 | — |
| SUNY Down State Medical Center | Brooklyn | New York | 11203 | — |
| VA Western New York Healthcare System | Buffalo | New York | 14215-1199 | — |
| North Shore Hematology Oncology Assoc., PC | East Setauket | New York | 11733 | — |
| Columbia Presbyterian Medical Center | New York | New York | 10032-3713 | — |
| VA Medical Center | Northport | New York | 11768 | — |
| Raleigh Hematology Oncology Association | Raleigh | North Carolina | 27609 | — |
| Clinical Research Services | Bismarck | North Dakota | — | — |
| University of Cincinnati, Barrett Cancer Center | Cincinnati | Ohio | 45267-0501 | — |
| Santee Hematology/Oncology | Sumter | South Carolina | 29150 | — |
| Associates in Oncology and Hematology | Chattanooga | Tennessee | 37404 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
| The Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Danville Hematology and Oncology | Danville | Virginia | 24541-4155 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Western Washington Oncology, Inc., P.S. | Lacey | Washington | 98503 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00072930, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2008 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00072930 live on ClinicalTrials.gov.